Skip to main content

Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership

Shanghai AlphaGen Therapeutics and ArtBio forged a far-reaching agreement to expand ArtBio’s market and develop new radioligand therapies. Additionally, Biocytogen Pharma signed an antibody evaluation/option agreement with Gilead Sciences.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.